resTORbio to Present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019
August 07, 2019 09:01 ET
|
resTORbio, Inc.
BOSTON, Aug. 07, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness
July 23, 2019 07:01 ET
|
resTORbio, Inc.
– Company plans to announce topline data from PROTECTOR 1 by early first quarter of 2020 – – PROTECTOR 2 is planned to start in the fourth quarter of 2019, with topline data expected in mid-2020 – ...
resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in Patients 65 Years of Age and Older with Asthma
May 20, 2019 08:00 ET
|
resTORbio, Inc.
RTB101 10 mg once daily was observed to reduce the rate of laboratory-confirmed Respiratory Tract Infections (RTIs) by 78.7% (p=0.001) and the rate of all RTIs (with or without laboratory...
resTORbio Reports First Quarter 2019 Financial Results and Corporate Update
May 15, 2019 08:00 ET
|
resTORbio, Inc.
Initiated first Phase 3 trial, PROTECTOR 1, of RTB101 in clinically symptomatic respiratory illness; top-line data from two pivotal Phase 3 trials expected in mid-2020 Initiated Phase 1b/2a trial of...
resTORbio Appoints Lloyd Klickstein, M.D., Ph.D., as Chief Scientific Officer
May 14, 2019 08:00 ET
|
resTORbio, Inc.
BOSTON, May 14, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio to Present RTB101 Phase 2b Clinical Trial Data at American Thoracic Society 2019 International Conference
May 13, 2019 08:00 ET
|
resTORbio, Inc.
BOSTON, May 13, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that it will present additional results from the Phase 2b trial evaluating RTB101 (dactolisib), an oral,...
resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory Illness
May 09, 2019 08:00 ET
|
resTORbio, Inc.
BOSTON, May 09, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), today announced the initiation of PROTECTOR 1, the first Phase 3 trial of RTB101, an orally administered, small molecule,...
resTORbio to Participate at Upcoming Investor Conferences in May
May 01, 2019 16:01 ET
|
resTORbio, Inc.
BOSTON, May 01, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio Announces Initiation of Phase 1b/2a Trial of RTB101 in Parkinson’s Disease
April 02, 2019 08:00 ET
|
resTORbio, Inc.
BOSTON, April 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio, Inc. Announces Closing Public Offering of Common Stock
March 22, 2019 10:02 ET
|
resTORbio, Inc.
BOSTON, March 22, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the...